1. Home
  2. USGO vs BNR Comparison

USGO vs BNR Comparison

Compare USGO & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. GoldMining Inc.

USGO

U.S. GoldMining Inc.

HOLD

Current Price

$7.49

Market Cap

104.5M

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$9.29

Market Cap

94.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USGO
BNR
Founded
2015
2014
Country
United States
China
Employees
10
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.5M
94.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
USGO
BNR
Price
$7.49
$9.29
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$30.75
N/A
AVG Volume (30 Days)
51.5K
13.8K
Earning Date
05-08-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.16
$5.96
52 Week High
$17.98
$41.72

Technical Indicators

Market Signals
Indicator
USGO
BNR
Relative Strength Index (RSI) 35.87 N/A
Support Level N/A N/A
Resistance Level $8.39 N/A
Average True Range (ATR) 0.38 0.00
MACD 0.01 0.00
Stochastic Oscillator 16.54 0.00

Price Performance

Historical Comparison
USGO
BNR

About USGO U.S. GoldMining Inc.

US Goldmining Inc is a mineral exploration company with a focus on the exploration and development of a project located in Alaska, USA. The company's primary asset is the 100%-owned Whistler exploration property located in Alaska, USA. It operates and reports in one segment, which focuses on the exploration and development of mineral properties.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: